Hepatitis

This trial tests a new vaccine called LBVD, which combines protection against six diseases: diphtheria, tetanus, whooping cough, hepatitis B, polio, and Hib. The study enrolls healthy infants around 6 to 8 weeks old who receive three doses at 6, 10, and 14 weeks of age. Researche…

This study looks at whether a second, inactivated hepatitis A vaccine can safely boost protection in healthy Thai children and teens who did not develop enough antibodies after a single dose of a live-attenuated hepatitis A vaccine. About 36 participants who took part in an earli…

This early-stage trial tests a new vaccine called AVX70371, designed to treat chronic hepatitis B by training the immune system to fight the virus. It involves 16 healthy adults aged 18 to 40 to check for safety and immune responses. The study is not yet testing if it works again…

This study tests an experimental drug, GSK4532990, in 284 adults with nonalcoholic steatohepatitis (NASH) and advanced liver scarring. The goal is to see if the drug can improve liver fibrosis and inflammation compared to a placebo over 52 weeks. Participants must have a liver bi…

This early-stage trial tests a therapeutic vaccine called ISA104 in 24 people with chronic hepatitis B who are already on antiviral drugs. The goal is to see if the vaccine is safe and can boost the immune system to better fight the virus. Participants will receive either ISA104 …

This early-stage trial tests a DNA vaccine called INO-8000, given with an immune booster, to see if it can help people with chronic hepatitis C fight the virus. The study involves 33 participants and focuses on safety and finding the best dose. The vaccine is delivered through in…

This Phase 2 study tests an experimental drug called ALG-000184 against a standard hepatitis B medication (tenofovir) in 200 adults with chronic hepatitis B. Participants take one pill daily for 48 weeks. The main goal is to see if the new drug can lower hepatitis B virus levels …

This Phase 2 trial tests whether adding TQ-A3334 tablets to standard nucleoside analog drugs can better control chronic hepatitis B. About 116 adults with the infection will receive either the combination or a placebo plus standard drugs. The main goal is to see if the combinatio…

Researchers are studying how the length of bypassed intestine during gastric bypass affects weight loss, complications, and metabolic changes in people with severe obesity. Participants will have different lengths of intestine bypassed and will provide blood and stool samples bef…

This study tests whether semaglutide, a medicine already used for type 2 diabetes, can help people with NASH, a serious liver condition. About 1205 adults with NASH and liver scarring (stage 2 or 3) will receive weekly injections of semaglutide or a placebo for up to 5 years. The…

This study tests a new drug combination (AZD9550 and AZD6234) for weight loss in 166 adults who are overweight or obese, with or without type 2 diabetes. The main goals are to check safety, tolerability, and how the drug moves through the body. It is an early-stage trial, so it f…

This study is testing a special kiosk placed in rural Appalachian Kentucky that provides clean syringes and harm reduction supplies to people who inject drugs. The goal is to see if the kiosk helps reduce the spread of HIV and hepatitis C, and lowers the risk of drug overdose. Ab…

This phase II trial tests whether lisinopril, a widely used blood pressure medication, can prevent liver damage from getting worse in people with non-alcoholic fatty liver disease (NAFLD). The study enrolls 45 adults with advanced liver scarring and measures changes in fibrosis m…

This trial tests whether a smartphone app and remote diet/exercise coaching can help people with non-alcoholic fatty liver disease lose weight and reduce liver fat. 120 participants will either get standard lifestyle advice or use the app with daily meal tracking, weekly recipe a…

This study tests an experimental drug called CS060380, taken with the weight-loss drug semaglutide, in adults with both fatty liver disease (MASH) and obesity. About 120 participants will be randomly assigned to get either CS060380 or a placebo for 36 weeks, then everyone gets CS…

This study tests an injection called AHB-137 in 20 adults with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if the drug can lower or eliminate hepatitis B surface antigen (HBsAg) and viral DNA, potentially leading to a functional cure. Parti…

This trial tests whether an estradiol patch can reduce liver fat and scarring in postmenopausal women with NASH, a progressive form of fatty liver disease. The study enrolls women aged 45-70 with NASH or fatty liver, giving them either a daily estradiol patch or a placebo for a p…

This early-stage study tests a drug called miricorilant in 8 people with MASH, a type of fatty liver disease linked to metabolism. The goal is to see if the drug can lower the amount of new fat the liver makes and reduce overall liver fat after 6 weeks. Participants must have cer…

This Phase 2 trial tests an experimental drug called AHB-137 in 105 adults with chronic hepatitis B who have not been treated before. The goal is to see if the drug can clear the hepatitis B surface antigen and lower the virus to undetectable levels, potentially leading to a func…

This phase 3 trial investigates whether bovine colostrum—the nutrient-rich first milk from cows—can improve survival in people with severe alcohol-associated hepatitis. The condition involves liver inflammation, a leaky gut, and a high risk of infection. Participants receive eith…

This early-stage study tests a new medicine called RO7790121 in 50 adults with advanced liver scarring from MASH (a type of fatty liver disease). The main goal is to see if the drug is safe and how the body processes it. Researchers will also check if it can reduce liver stiffnes…

This Phase 3 trial tests whether a combination of two drugs, tobevibart and elebsiran, can suppress hepatitis D virus in adults who are still infected despite taking bulevirtide. About 150 participants will receive the combo as injections. The main goal is to see if the virus bec…

This study tests a new drug called bepirovirsen in 153 people who have both HIV and chronic hepatitis B and are already on HIV treatment. The goal is to see if bepirovirsen can clear the hepatitis B virus from the body better than a placebo. Participants will continue their regul…

This phase 3 study tests whether a daily pill called resmetirom can prevent serious liver events like liver failure, need for transplant, or bleeding in people with NASH cirrhosis. About 845 adults with well-compensated cirrhosis will receive either the drug or a placebo. The goa…

This study tests whether giving two experimental drugs in sequence can achieve a functional cure for chronic hepatitis B. Participants are adults with chronic HBV who are already on standard antiviral therapy. They will receive either one of two doses of daplusiran/tomligisiran f…

This study tests a drug called lanifibranor in 1000 adults with NASH (a fatty liver disease) and moderate liver scarring (stages F2 or F3). The goal is to see if the drug can reverse the scarring and reduce liver inflammation over 72 weeks. Participants are randomly assigned to r…

This Phase 3 trial tests a drug called brelovitug (BJT-778) in 80 people with chronic hepatitis delta, a serious liver infection. Participants receive either brelovitug or delayed treatment to see if the drug can lower virus levels and improve liver enzyme counts. The study is re…

This study tests a new two-drug combination, BEM/RZR, against an approved treatment, SOF/VEL, in 880 adults with chronic hepatitis C. The goal is to see if BEM/RZR can clear the virus as effectively and safely. Participants must not have taken prior HCV drugs and may have compens…

This phase 2 trial tests two experimental drugs, Elebsiran and Tobevibart, in 95 adults with chronic hepatitis D, a serious liver infection. Participants receive the drugs as injections along with a standard oral antiviral. The goal is to see if the combination can lower virus le…

This study looks at two antiviral drugs, TAF and TDF, in pregnant women with chronic hepatitis B. It aims to see which one better controls the virus and keeps the mother's liver healthy without harming the baby. About 816 women in early or middle pregnancy will take one of the dr…

This study tests a drug called tenofovir alafenamide (TAF) in 150 children and teens with chronic hepatitis B. Half receive TAF and half receive a placebo for 24 weeks. Researchers are checking how safe the drug is, how the body processes it, and whether it lowers virus levels. T…

This study provides access to the drug bulevirtide (Hepcludex®) for people with chronic hepatitis delta virus infection who have compensated liver disease (with or without cirrhosis). Participants must meet specific health criteria, including a positive HDV RNA test. The goal is …

This study tests whether a special formula diet can help people with non-alcoholic fatty liver disease (NASH) lose weight and improve liver health. About 20 overweight adults will follow the diet to see if it reduces liver fat and scarring. The goal is to find a safe, effective w…

This study tests whether using a dried blood spot test (a simple finger prick) can help people with hepatitis C start treatment faster than the usual method that requires a blood draw. The trial involves 141 participants who work with a peer support program and telemedicine. The …

This Phase 3 trial tests whether the drug resmetirom (MGL-3196) can reverse liver scarring (fibrosis) and stop NASH from progressing to cirrhosis or liver failure. About 1,759 adults with NASH and liver fibrosis will receive either resmetirom or a placebo daily for up to 54 month…

This study tests whether the antiviral drug entecavir can prevent hepatitis B from reactivating in people with a type of blood cancer (CD20-positive B-cell lymphoma) who have had hepatitis B in the past but cleared it. The 84 participants will take entecavir before starting their…

This study tests whether lungs from donors with hepatitis C can be safely transplanted into people without the virus. The lungs are treated with a special machine to try to reduce the virus. If the recipient gets infected, they will be treated with standard antiviral medication. …

This study tests an experimental drug called miricorilant in 175 adults with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease. Participants are randomly assigned to receive either the drug or a placebo, and researchers measure changes in liver fat using MRI scan…

This phase 3 trial tests an experimental drug called AHB-137 in 577 adults with HBeAg-negative chronic hepatitis B who are already on standard antiviral pills. Participants receive weekly injections of AHB-137 or a placebo for a set period, then stop all hepatitis B treatment. Th…

This study looks at switching kidney or liver transplant patients with chronic hepatitis B to a drug called tenofovir alafenamide (TAF). The goal is to see if TAF is safer for the kidneys, controls the virus well, and is easier for patients to stick with. The study involves 52 ad…

This study tests a 12-week course of three antiviral drugs (sofosbuvir, velpatasvir, and voxilaprevir) in 200 adults with chronic hepatitis C whose virus returned after previous treatment. The main goal is to see if the virus becomes undetectable 12 weeks after therapy ends. Rese…

This Phase 3 study tests whether efruxifermin, given as a weekly shot, is safe and can improve liver health in 700 adults with NASH/MASH (a type of fatty liver disease). Participants receive either the drug or a placebo. The study tracks side effects and measures changes in liver…

This study is testing a drug called pradefovir mesylate in 400 adults with chronic hepatitis B. The goal is to see how well it lowers the virus and how safe it is in everyday medical practice, not just in a strict research setting. Participants are being followed for up to 65 wee…

This study looks at whether eating three soybean-oil-based foods each day for 16 weeks can lower fat buildup in the liver and belly fat in people with nonalcoholic fatty liver disease. Participants keep their usual weight during the trial. The goal is to see if changing the type …

This study tests two antiviral medications, TAF and TDF, in 200 pregnant women with chronic hepatitis B. The goal is to see which drug better prevents passing the virus to the baby and causes fewer birth defects or side effects. Participants take the drug daily during pregnancy a…

This study monitors 45 people with chronic hepatitis B who already received the experimental gene editing treatment PBGENE-HBV in an earlier trial. Researchers will watch for any delayed side effects over time. No new treatment is given; the goal is to understand the long-term sa…

This study tests whether peer mentors—people with similar experiences—can help individuals recently released from jail or prison get connected to Hepatitis C care and stay in treatment. About 80 participants will either receive a peer mentor or standard referral. The goal is to s…

This study tests whether a monitored ketogenic diet is safe and effective for weight loss in 40 obese adults with compensated NASH cirrhosis. Participants are randomly assigned to either a ketogenic diet or standard dietary advice for 16 weeks. The main goals are to check for liv…

This study tests a 12-week course of the drug Sofosbuvir/Velpatasvir in about 100 pregnant women with chronic hepatitis C. The goal is to see if the treatment can cure the virus and whether it affects the timing of delivery. Mothers are followed for 12 weeks after treatment, and …

This study tests a combination of two drugs, atezolizumab and bevacizumab, in 51 people with advanced liver cancer who also have chronic hepatitis B. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the drugs every three weeks, a…

This phase 3 study tests whether a combination of two drugs, tobevibart and elebsiran, can control chronic hepatitis delta better than waiting for treatment. About 124 adults with the infection will receive either the combo therapy or delayed treatment. The goal is to see if the …

This study tests a program where trained peers use motivational interviewing to encourage people who use drugs to check their drugs for dangerous substances and adopt safer use behaviors. The goal is to reduce fatal and non-fatal overdoses, as well as HIV and hepatitis C infectio…

This study compares two diabetes medications, semaglutide and sitagliptin, in 58 adults who have had a liver transplant and have poorly controlled diabetes. The goal is to see which drug better lowers blood sugar and body weight. Participants will take the study drug daily for th…

This pilot study tests whether adding a PD-1 antibody (sintilimab) and pegylated interferon to standard antiviral therapy can help people with chronic hepatitis B lose the hepatitis B surface antigen (HBsAg), a key step toward a functional cure. The trial will enroll 45 adults wh…

This early-stage study tests a new drug called CS060304 in healthy volunteers and people with high LDL-C (bad cholesterol), a risk factor for MASH (a serious liver disease). The main goal is to check if the drug is safe and how the body processes it. 80 participants will receive …

This phase 2 trial is testing an experimental drug called VSA006 in 48 Chinese adults with NASH, a type of fatty liver disease that can lead to cirrhosis. VSA006 is an RNA-based drug designed to lower a liver protein linked to disease progression. The study compares VSA006 inject…

This study tests an experimental drug called efinopegdutide in 80 adults with liver scarring (cirrhosis) caused by metabolic dysfunction-associated steatohepatitis (MASH), a type of fatty liver disease. The goal is to see if the drug can reduce liver fat, inflammation, and scarri…

This study tests a new medicine called BJT-778 for people with chronic hepatitis delta, a serious liver infection. About 150 adults will either start the drug right away or wait 24 weeks before starting. The goal is to see if the drug can lower the virus level and improve liver h…

This study looks at 260 chronic hepatitis B patients who stopped their antiviral medication and then had a flare-up. They are switched to a drug called tenofovir alafenamide (TAF) to see if it can control the virus and improve liver health. The goal is to measure how many patient…

This study tests a drug called Aramchol for people with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease that can lead to scarring. About 150 adults with NASH and liver scarring (stages 1-3) will take Aramchol or a placebo for up to 72 weeks. The goal is to see …

This study tests an experimental drug called RBD1016 in 14 adults with chronic hepatitis D, a serious liver infection. The main goal is to see if the drug can lower the amount of virus in the blood over 60 weeks. Participants receive either RBD1016 or a placebo and visit the clin…

This study tested an antiviral drug called tenofovir in children aged 2 to 12 with chronic hepatitis B. The goal was to see if the drug could lower the amount of virus in their blood compared to a placebo. The trial involved 90 children and measured safety and effectiveness over …

This study tests whether empagliflozin, a diabetes drug, can prevent liver scarring (fibrosis) from getting worse in people with chronic hepatitis B. About 106 participants with moderate to severe liver scarring will take either empagliflozin or a placebo daily for three years. T…

This study tests whether atorvastatin (Lipitor), a widely used cholesterol medication, can safely improve liver damage in people with NASH, a serious fatty liver disease. About 70 adults with confirmed NASH and liver scarring will receive either the drug or a placebo. The goal is…

This Phase 2 trial tests whether a new injection called BW-20507, combined with pegylated interferon alfa, can help people with chronic hepatitis B stop their daily antiviral medication (NUCs). About 209 adults with hepatitis B will receive the combination for 48 weeks. The main …

This study tests whether a combination of two experimental drugs (Tobevibart and Elebsiran) works better than the current treatment Bulevirtide for people with chronic hepatitis D, a serious liver infection. About 100 adults with stable liver disease will receive either the combo…

This study follows 30 adults with chronic hepatitis C (genotype 3) and mild to moderate liver fibrosis who are taking ravidasvir and sofosbuvir as part of their regular care. Researchers will check if the virus is undetectable 12 weeks after treatment ends (SVR12). The goal is to…

This study was designed to test ARC-520, an experimental RNAi drug, in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if adding ARC-520 could lower hepatitis B surface antigen levels more effectively. However, the trial…

This Phase 2 trial tests a new drug called hepalatide (L47) in 90 adults with chronic hepatitis D, a serious liver infection. Participants receive either a low or high dose of hepalatide daily for 48 weeks, or delayed treatment. The main goal is to see if the drug can lower the v…

This study tests whether special ice creams made with natural sweeteners (brazzein, maltitol, erythritol, and fibers) can help control blood sugar and be easier on digestion than regular ice cream. One hundred adults with non-alcoholic fatty liver disease and type 2 diabetes will…

This study looks at whether a combination of four herbs (Phyllanthus urinaria, Adenosma glutinosum, Eclipta prostrata, and ascorbic acid) plus the drug tenofovir can help control hepatitis B over the long term. The treatment aims to strengthen the immune system and reduce virus l…

This Phase 3 trial compares a new two-drug combination pill (Bemnifosbuvir-Ruzasvir) against the current standard treatment (Sofosbuvir-Velpatasvir) for adults with chronic hepatitis C. About 880 participants who have not been treated with similar drugs before will take the new p…

This study is testing a combination of two antiviral drugs, sofosbuvir and daclatasvir, in children aged 6 and older with active hepatitis C in Cambodia. The goal is to see if the treatment can clear the virus from the blood 12 weeks after finishing the 12-week course. The trial …

This study looks at whether a non-surgical stomach reduction procedure (endoscopic sleeve gastroplasty) can improve liver health in people with obesity and advanced NASH (a severe form of fatty liver disease). Twenty adults with obesity and biopsy-confirmed NASH with advanced sca…

This study tests two experimental injections, HT-101 and HT-102, in 60 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if the combination can lower hepatitis B virus levels to undetectable and help the immune system control the in…

This study is for people in Pakistan with hepatitis C who did not get cured by their first treatment. It compares two different lengths of treatment with the drug Epclusa (12 weeks vs 24 weeks) to see which works better. About 318 adults will take part, and the goal is to find th…

This study tests a drug called Tenofovir Amibufenamide (TMF) in 200 adults with chronic hepatitis B who have normal liver enzyme levels (ALT). The goal is to see if TMF can lower the virus to undetectable levels and possibly clear the hepatitis B surface antigen. Participants are…

This study tests whether kidneys from donors with hepatitis C can be safely transplanted into people without the virus. Recipients will take the antiviral drug Epclusa for 12 weeks to prevent or treat infection. The goal is to see if this approach is safe and effective, potential…

This study tests a new medication called hepenofovir fumarate (HTS) for people with chronic hepatitis B, a long-term liver infection. About 1,444 adults aged 18-65 who have not been treated before (or stopped treatment at least 6 months ago) will take one of three doses of HTS or…

This early-stage trial tests a new vaccine called TVAX-008 in 20 adults with chronic hepatitis B who have very low levels of the virus. The goal is to see if the vaccine can safely boost the body's immune response, potentially helping control the infection. Participants will be m…

This Phase 2 trial tests an injection called TVAX-008 in 80 adults with chronic hepatitis B who are already on antiviral pills. Half get TVAX-008 plus their usual medication, half get a placebo plus their usual medication, for 24 weeks. The goal is to see if TVAX-008 can make the…

This study tests whether a polyester mesh coated with fluoropolymer can reduce complications after breast reconstruction in women with breast cancer. One hundred women will receive either standard reconstruction or reconstruction with the coated mesh. The main goal is to see if t…

This early-stage trial tests two new injections (HT-101 and HT-102) in 86 people with chronic hepatitis B. Participants receive the shots every 4 weeks, along with standard antiviral pills. The main goal is to check safety and how the body processes the drugs, while also looking …

This Phase 2 trial tests an injection called TVAX-008 in 48 adults with chronic hepatitis B who have low levels of the virus. Half receive the drug, half a placebo, to see if it can clear a key virus marker (HBsAg) safely. The study is double-blind and already finished enrolling.

This study aims to eliminate hepatitis C among people who use drugs in Paris, Marseille, Lyon, and Fort-de-France. Researchers will screen participants, provide immediate treatment, and use a peer-referral system to reach more people. The goal is to see if this community-based ap…

This phase 2 study tests whether adding the experimental drug BRII-835 to standard pegylated interferon can help people with chronic hepatitis B lose the virus surface antigen (HBsAg), a key marker of infection. Eighty-six adults on stable antiviral therapy will receive either in…

This study tests whether combining artificial intelligence with blood biomarkers can improve the detection of compensated advanced chronic liver disease (cACLD) in people with fatty liver disease. Researchers will enroll 408 adults with dysmetabolic liver disease and compare stan…

This study was designed to test a new thermo-acoustic imaging device that may help diagnose fatty liver disease without invasive procedures. It would have compared the device's accuracy to standard MRI scans in adults aged 18-70 with known or suspected fatty liver. However, the s…

This study follows 300 children aged 9 to 14 with obesity to see if ultrasound and MRI can detect early signs of liver disease. Researchers will compare imaging markers like liver fat and stiffness with standard tests. The goal is to improve diagnosis and monitoring without invas…

This study is testing whether adding a blood test called the GAAD score to regular ultrasound scans can improve the detection of liver cancer in people at high risk, such as those with cirrhosis or chronic hepatitis. About 2,100 participants will get both tests every six months f…

This study aims to see if a special MRI scan can accurately detect liver scarring (fibrosis) in people with a liver condition called MASH. Researchers will compare the MRI results with standard tests like ultrasound and blood work in 50 adults. If successful, this could offer a n…

This study looks at whether two blood markers, PLIN2 and RAB14, can accurately diagnose NASH (a serious liver disease) and advanced scarring, without needing a liver biopsy. Researchers will test these markers in 828 adults with NASH, type 2 diabetes, or obesity. If successful, t…

This study tests a new MRI technique that measures liver fat, fibrosis, and inflammation in a single 14-second breath-hold, without needles or contrast dye. Researchers will scan 120 people with fatty liver disease (60 with simple steatosis and 60 with NASH) and compare results t…

This study is testing whether a new blood test score, called GAAD, can detect liver cancer earlier in people with chronic liver disease. The GAAD score combines a person's gender, age, and two blood markers (AFP and PIVKA-II). Researchers will compare the GAAD score to standard u…

This study is testing a new blood test called Oncoguard Liver to see how well it detects liver cancer (hepatocellular carcinoma) in people at increased risk, such as those with cirrhosis or hepatitis B. About 3,000 participants will provide a blood sample and undergo imaging like…

This phase 3 trial tests whether giving antiviral medication to pregnant women with hepatitis B and their newborns can prevent the virus from passing to the baby. The study involves 450 women and their infants in Africa. The goal is to find a safe and effective way to reduce moth…

This pilot trial tests whether training Gancheros—people who provide injection services in exchange for money or drugs—can lower HIV, hepatitis C, and overdose risks among migrant Puerto Rican people who inject drugs in New York City. Gancheros will attend six sessions on prevent…

This study tests whether providing HIV prevention (PrEP) and hepatitis C treatment together at one location works better than sending patients to separate clinics. About 446 people who inject drugs will be randomly assigned to either on-site integrated care or off-site referrals …

This study tests whether a short course of two drugs (glecaprevir/pibrentasvir and ezetimibe) can prevent hepatitis C infection in people who receive a kidney, heart, lung, or pancreas from a donor with hepatitis C. About 200 participants who are hepatitis C-negative will take th…

Researchers test whether repeated cold exposure using a water-perfused cooling suit can reduce liver fat and improve liver health in adults with metabolic dysfunction-associated steatohepatitis (MASH). Eleven participants wear the suit for about two hours daily over three months.…

This study follows 500 obese adults to see how different factors like diet, exercise, stress, and sleep affect weight loss. Researchers collect blood tests, measurements, and questionnaires at the start and during follow-up. The goal is to find patterns that could lead to more pe…

Researchers are testing a coaching program to help primary care clinics in rural West Virginia screen and treat opioid use disorder, HIV, and hepatitis C. The program includes group priority-setting, rapid-cycle improvement coaching, and provider training. Twenty clinics will tak…

This study follows 121 adults who have been cured of chronic hepatitis C to understand why some still develop liver complications like scarring or cancer. Participants are monitored for up to 10 years with regular tests, scans, and occasional liver biopsies. The goal is to learn …

This completed study observed 40 people with type 2 diabetes to find blood markers that could identify those at risk for a serious liver condition called NASH. Researchers measured liver stiffness and calculated scores like FIB-4 and ELF to see which patients might have liver sca…

This study looks at liver health in transgender people who are on gender-affirming hormone therapy (GAHT). It compares those who have been on hormones for more than six months with those on them for less time. Researchers will measure liver function through blood tests and a spec…

This study looks at medical records from 10,000 adults with MASLD or MASH, a common liver condition. Researchers will check if changes in liver stiffness, measured by a non-invasive scan called FibroScan, are linked to future serious liver problems like cirrhosis, liver cancer, o…

This study follows 2,002 people at high risk for liver cancer to find better ways to detect it early. Researchers are testing a panel of blood-based miRNA markers, gut microbiome changes, and MRI-based AI algorithms to predict who develops the disease. The goal is to improve on c…

This study follows people with chronic hepatitis B or C for up to 10 years to track how the disease changes over time. A smaller group with hepatitis B will receive the drug tenofovir alafenamide for 2 years to see if it reduces liver stiffness. Participants provide blood samples…

This study looks at how chronic hepatitis B virus (HBV) infection affects natural killer (NK) cells, which are key immune cells that fight infections. Researchers will collect blood samples from 80 people with HBV and compare them to healthy donors. The goal is to understand why …

This study follows about 360 people with chronic hepatitis B who had a good response to the experimental drug bepirovirsen in earlier trials. No new drug is given; researchers simply monitor whether the response lasts over time. Participants may or may not continue standard antiv…

This study looks at 300 patients with advanced liver scarring (cirrhosis) caused by hepatitis B or alcohol who have shown signs of getting better. Researchers want to understand what predicts this improvement and how long it lasts. The goal is to create clearer guidelines for whe…

This study looks at how the liver burns fat and makes sugar in people with NASH (a serious liver disease linked to obesity) who are planning to have weight-loss surgery. Researchers will use special scans to measure liver function before and after surgery in 30 adults. The goal i…

This study tests a program where veteran peer workers provide education, healthcare navigation, and social support to 150 veterans with opioid use disorder who are not connected to VA healthcare. The goal is to reduce risky behaviors related to overdose and HIV/HCV infection. Res…

This study looks at how often people with type 1 diabetes have fatty liver disease and serious liver scarring. Researchers used a special ultrasound and blood tests to check 533 adults. The goal is to find high-risk patients who need a liver specialist.

This study gives a single dose of bepirovirsen to 32 adults with hepatitis B, some with kidney disease and some healthy. Researchers measure how much drug gets into the blood and how long it stays. The goal is to see if kidney problems change drug levels, which could affect futur…

This study follows 60 healthy Thai children and teens who received a single dose of a live-attenuated hepatitis A vaccine about a year ago. Researchers want to see how many still have protective antibodies and at what levels. The goal is to understand long-term immunity and help …

This study was designed to collect information on pregnancy and baby outcomes in women who received the PREHEVBRIO hepatitis B vaccine around the time of conception or during pregnancy. The goal was to watch for any safety concerns, such as miscarriage or birth defects. However, …

This study planned to see if faster testing and treatment for hepatitis C could be given to inmates right when they enter prison. The goal was to start medication sooner to reduce the spread of the virus. However, the study was withdrawn and no one took part.

This study tests a new, longer MRI scan that measures liver stiffness and viscosity to see if it can identify NASH patients at higher risk for liver cancer. About 35 adults with NASH and early-stage liver scarring will participate. The goal is to improve early detection, not to t…

This study follows 1,689 adults with fatty liver disease (MASLD) or MASLD with increased alcohol intake (MetALD) to see if non-invasive tests like MRI and Fibroscan can accurately track disease progression. The goal is to reduce the need for liver biopsies in future research and …

This study looks at whether people with chronic hepatitis delta who have been on bulevirtide for at least 48 weeks and have very low virus levels can safely stop treatment. Researchers will monitor 20 participants for 48 weeks after stopping to find biological markers that predic…

This study follows 54 people with chronic hepatitis B who stop taking their antiviral medication after at least three years. Researchers will closely monitor their immune system and virus levels to see what happens during a flare. The goal is to learn whether a controlled flare m…

This study uses artificial intelligence to analyze data from 5,000 people with autoimmune hepatitis. The goal is to create a computer model that can predict which patients will respond well to standard therapy within 6 to 12 months. By identifying these patterns early, doctors ma…

This study looks at how the immune system behaves in people with chronic hepatitis B. Researchers are measuring different immune cells and signals to understand why some people control the virus better than others. 201 adults already enrolled in a larger hepatitis B study are pro…

This study looks at how the immune system responds to chronic hepatitis B infection. Researchers will analyze blood samples from 40 adults already enrolled in larger treatment trials. The goal is to understand why some people respond better to therapy and how the disease progress…

This study follows 400 adults with HIV to learn how nonalcoholic fatty liver disease (NAFLD) develops and progresses in this group. Researchers will use a non-invasive scan to measure liver stiffness and fat content over one year. The goal is to fill major knowledge gaps, since p…

This study tests whether sending mailed invitations and assigning patient navigators can increase the number of high-risk patients who attend regular liver cancer ultrasound screenings. The trial includes 652 adults with cirrhosis or chronic hepatitis B, who are at risk for hepat…

This observational study follows 1,222 adults with liver cirrhosis to understand why some develop serious complications like fluid buildup or bleeding. Participants have check-ups every six months, including questionnaires, physical exams, and imaging. The goal is to build better…

This observational study plans to enroll 120,000 people with various chronic diseases like pancreatitis, diabetes, and arthritis. Researchers will collect blood samples and health data to study how genetics and lifestyle affect disease progression. The goal is to find common dise…

This study follows 60 cancer patients who have a hidden form of hepatitis B (occult infection) and are receiving immunotherapy. The goal is to see how often the virus becomes active again, which could cause liver problems. Researchers will monitor blood tests and immune responses…

This study aims to understand how bariatric surgery affects the body's tissues, like fat, muscle, and liver, and how it improves insulin sensitivity. Researchers will collect tissue and blood samples from 500 adults undergoing surgery or other procedures. The goal is to learn the…

This study follows 300 patients with severe alcoholic hepatitis who receive early liver transplants, before the usual 6-month sobriety period. Researchers will track how many survive one year after transplant and how many return to drinking. The goal is to better understand the r…

This study tests whether MRI and ultrasound can accurately measure liver fat in children aged 10-14, both those with obesity and those at a healthy weight. Researchers will check if the scans are reliable and easy to perform. The goal is to develop a non-invasive tool to diagnose…

This study tests whether special PET scans can accurately measure fat, swelling, and scarring in the liver of people with non-alcoholic fatty liver disease (NAFLD). Researchers will compare scan results with standard liver biopsies from 120 adults. If successful, this could lead …

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…

This observational study follows 11 patients with chronic hepatitis B and delta coinfection and liver cirrhosis who are already receiving the antiviral drug Bulevirtide. Researchers want to see if suppressing the virus reduces portal hypertension—a dangerous buildup of pressure i…